Cytoplasmic and nuclear programmed death ligand 1 expression in peritumoral stromal cells in breast cancer: Prognostic and predictive value

Table 4 Distribution of patients with different degrees of programmed cell death protein 1 ligand 1-positive polymorphic cell infiltration, n (%)

Breast cancer characteristics	Degrees of PDCD1 LG1+ polymorphic cell infiltrations		P value χ² tests
	No, weak	Moderate, pronounced
T stage
Тis	2 (50.0)	2 (50.0)	0.02
Т1в	4 (36.4)	7 (63.6)
Т1с	59 (66.3)	30 (33.7)
Т2	36 (81.8)	8 (18.2)
N stage
N0	58 (71.6)	23 (28.4)	0.70
N1	31 (66.0)	16 (34.0)
N2	10 (62.5)	6 (37.5)
N3	2 (50.0)	2 (50.0)
Tumor grade (G)
G1	10 (62.5)	6 (37.5)	0.09
G2	68 (74.7)	23 (25.3)
G3	23 (56.1)	18 (43.9)
Lymphovascular invasion
No	60 (71.4)	24 (28.6)	0.34
Yes	41 (64.1)	23 (35.9)
Perineural invasion
No	79 (68.7)	36 (31.3)	0.82
Yes	22 (66.7)	11 (33.3)
ER status
Negative	5 (31.3)	11 (68.7)	0.0008
Positive	96 (72.7)	36 (27.3)
PR status
Negative	25 (60.9)	16 (39.0)	0.23
Positive	76 (71.0)	31 (29.0)
HER2 status
HER2 -	99 (77.3)	29 (22.7)	< 0.00001
HER2+	2 (10.0)	18 (90.0)
Molecular biological subtype
Luminal A	42 (75.0)	14 (25.0)	< 0.00001
Luminal B HER2-	54 (81.8)	12 (18.2)
Luminal B HER2+	0 (0)	10 (100)
Nonluminal HER2+	2 (20.0)	8 (80.0)
TNBC	3 (50.0)	3 (50.0)

ER: Estrogen receptor; HER2: Human epidermal growth factor receptor 2; PR: Progesterone receptor; TNBC: Triple-negative breast cancer; PDCD1 LG1: Programmed cell death protein 1 ligand 1.